Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: A gruppo oncologico dell'Italia meridionale multicenter phase II study

Oncology

Volumn 79, Issue 5-6, 2011, Pages 415-422

  Colucci, Giuseppe ^a   Giuliani, Francesco ^a   Garufi, Carlo ^b   Mattioli, Rodolfo ^c   Manzione, Luigi ^d   Russo, Antonio ^e   Lopez, Massimo ^b   Parrella, Paola ^f   Tommasi, Stefania ^a   Copetti, Massimiliano ^f   Daniele, Bruno ^g   Pisconti, Salvatore ^h   Tuveri, Guido ⁱ   Silvestris, Nicola ^a   Maiello, Evaristo ^f  

^a NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c General Hospital   (Italy)

^d SAN CARLO HOSPITAL   (Italy)

^e UNIVERSITY OF PALERMO   (Italy)

^f CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^g General Hospital   (Italy)

^h SS Annunziata Hospital   (Italy)

ⁱ General Hospital   (Italy)

Author keywords

BRAF; Cetuximab; Colorectal carcinoma; FOLFOX 4; KRAS; Metastases

Indexed keywords

B RAF KINASE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER SCREENING; CANCER SURVIVAL; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LIVER DISEASE; LIVER RESECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SKIN TOXICITY; THROMBOCYTOPENIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79953710056     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323279     Document Type: Article

References (25)

1. Kelly H, Goldberg RM: Systemic therapy for metastatic colorectal cancer: current options, current evidence. J Clin Oncol 2005; 23: 4553-4560. (Pubitemid 46196586)
2. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX-6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237. (Pubitemid 41095086)
3. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Cartenì G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C: Phase III randomized trial of FOLFIRI versus FOLFOX-4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico dell'Italia Meridionale. J Clin Oncol 2005; 23: 4866-4875. (Pubitemid 46223991)
4. Wells A: EGF receptor. Int J Bioch Cell Biol 1999; 31: 637-643. (Pubitemid 29248872)
5. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810. (Pubitemid 46211358)
6. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008; 358: 1160-1174.
7. Saltz L, Meropol NJ, Loehrer PJ, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208. (Pubitemid 41079832)
8. Lenz HJ, van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, Mirtsching B, Cohn AL, Pippas AW, Azarnia N, Tsuchihashi Z, Mauro DJ, Rowinsky EK: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006; 24: 4914-4921. (Pubitemid 46630920)
9. Prewett M, Deevi DS, Bassi R, Fan F, Ellis LM, Hicklin DJ, Tonra JR: Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res 2007; 13: 7432-7440.
10. Tabernero J, van Cutsem E, Díaz-Rubio E, Cervantes A, Humblet Y, André T, van Laethem JL, Soulié P, Casado E, Verslype C, Valera JS, Tortora G, Ciardiello F, Kisker O, de Gramont A: Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25: 5225-5232. (Pubitemid 350232254)
11. Arnold D, Höhler T, Dittrich C, Lordick F, Seufferlein T, Riemann J, Wöll E, Herrmann T, Zubel A, Schmoll HJ: Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Ann Oncol 2008; 19: 1442-1449.
12. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671.
13. Silvestris N, Tommasi S, Santini D, Russo A, Simone G, Petriella D, Maiello E, Tonini G, Colucci G: KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue. Expert Opin Biol Ther 2009; 9: 565-577.
14. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009; 27: 2091-2096.
15. di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, de Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26: 5705-5712.
16. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes- Funes H, Cervantes A, Freyer G, Papamichael D, le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947. (Pubitemid 30644117)
17. Therasse P, Arbuck SG, Eisenhauer E: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
18. Dakhil S, Cosgriff T, Headley D, et al: Cetuximab + FOLFOX-6 as first-line therapy for metastatic colorectal cancer. An International Oncology Network study, I-03-002 (abstract 3557). J Clin Oncol 2006; 24(18 suppl):3557a.
19. Seufferlein T, Dittrich C, Riemann JF, Woell E, Herrmann T, Lordick F, Arnold D, Olchowka K, Höhler T, Schmoll HJ: A phase I/II study of cetuximab in combination with 5-fluorouracil (5-FU)/folinic acid (FA) plus weekly oxaliplatin (L-OHP) (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer (mCRC) expressing epidermal growth factor receptor (EGFR): preliminary results (abstract 3644). J Clin Oncol 2005; 23(16 suppl):3644a.
20. Venook A, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S, Benson A, Wade J, Schilsky R, Mayer R: Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/ 5FU/LV (FOLFOX) 8 cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 2006; 24(18 suppl):3509a.
21. Jamison RL, Donohue JH, Nagorney DM, Rosen CB, Harmsen WS, Ilstrup DM: Hepatic resection for metastatic colorectal cancer results in cure for some patients. Arch Surg 1997; 132: 505-510.
22. Adam R, Delvart V, Pascal G, Valeanu A, Castaing D, Azoulay D, Giacchetti S, Paule B, Kunstlinger F, Ghémard O, Levi F, Bismuth H: Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 2004; 240: 644-658. (Pubitemid 39281287)
23. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH: Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumor response and resection rates. Ann Oncol 2005; 16: 1311-1319. (Pubitemid 41158476)
24. Aloia T, Sebagh M, Plasse M, Karam V, Lévi F, Giacchetti S, Azoulay D, Bismuth H, Castaing D, Adam R: Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24: 4983-4990. (Pubitemid 46631400)
25. van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.